Targeting pleiotropin to treat osteoarthritis

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 7, 2007, Pages 861-867

  Mentlein, Rolf ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Cartilage; Chondrocyte; Growth factor; Midkine; Osteoarthritis; Pleiotropin; Signal transduction

Indexed keywords

ANTIOXIDANT; CAPSAICIN; COLLAGEN TYPE 1; CYCLOOXYGENASE 2 INHIBITOR; GROWTH FACTOR; HYDROCORTISONE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LIDOCAINE; MESSENGER RNA; OPIATE; PARACETAMOL; PLEIOTROPHIN; SALICYLIC ACID DERIVATIVE; TRAMADOL;

BONE DEVELOPMENT; BONE REGENERATION; BONE REMODELING; CHONDROGENESIS; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; NONHUMAN; OSTEOARTHRITIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; ARTHRITIS, RHEUMATOID; BONE AND BONES; CARRIER PROTEINS; CHONDROCYTES; CYTOKINES; HUMANS; OSTEOARTHRITIS; SIGNAL TRANSDUCTION;

EID: 34447309030     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.7.861     Document Type: Review

References (59)

1. SANDELL LJ, AIGNER T: Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res. (2001) 3:107-113.
2. GOLDRING MB. Anticytokine therapy for osteoarthritis. Expert Opin. Biol. Ther. (2001) 1:817-829.
3. PUFE T, PETERSEN W, TILLMANN B, MENTLEIN R: The splice variants VEGF 121 and VEGF 189 of the angiogenic peptide vascular endothelial growth factor are expressed in osteoarthritic cartilage. Arthritis Rheum. (2001) 44:1082-1088.
4. PUFE T, LEMKE A, KURZ B et al.: Mechanical overload induces VEGF in cartilage discs via hypoxia-inducible factor. Am. J. Pathol. (2004) 164:185-192.
5. GERBER HP, VU TH, RYAN AM, KOWALSKI J, WERB Z, FERRARA N: VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. (1999) 5:623-628.
6. KURTZ A, SCHULTE AM, WELLSTEIN A: Pleiotrophin and midkine in normal development and tumor biology. Crit. Rev. Oncog. (1995) 6:151-177.
7. ZHANG N, DEUEL TF: Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors. Curr. Opin. Hematol. (1999) 6:44-50.
8. HAYNES L, RUMSBY M: The pleiotropin/midkine family of cytokines: role in glial-neuronal signalling. Prog. Brain Res. (2001) 132:313-324.
9. DEUEL TF, ZHANG N, YEH HJ, SILOS-SANTIAGO I, WANG ZY: Pleiotrophin: a cytokine with diverse functions and a novel signaling pathway. Arch. Biochem. Biophys. (2002) 397:162-171.
10. MURAMATSU T: Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J. Biochem. (Tokyo) (2002) 132:359-371.
11. KADOMATSU K, MURAMATSU T: Midkine and pleiotrophin in neural development and cancer. Cancer Lett. (2004) 204:127-143.
12. VANDERWINDEN JM, MAILLEUX P, SCHIFFMANN SN, VANDERHAEGHEN JJ: Cellular distribution of the new growth factor pleiotrophin (HB-GAM) mRNA in developing and adult rat tissues. Anat. Embryol. (Berl) (1992) 186:387-406.
13. NEAME PJ, YOUNG CN, BROCK CW et al.: Pleiotrophin is an abundant protein in dissociative extracts of bovine fetal epiphyseal cartilage and nasal cartilage from newborns. J. Orthop. Res. (1993) 11:479-491.
14. DREYFUS J, BRUNET-DE CARVALHO N, DUPREZ D, RAULAIS D, VIGNY M: HB-GAM/ pleiotrophin: localization of mRNA and protein in the chicken developing leg. Int. J. Dev. Biol. (1998) 42:189-198.
15. AZIZAN A, GAW JU, GOVINDRAJ P, TAPP H, NEAME PJ: Chondromodulin I and pleiotrophin gene expression in bovine cartilage and epiphysis. Matrix Biol. (2000) 19:521-531.
16. PETERSEN W, RAFII M: Immunolocalization of the angiogenetic factor pleiotrophin (PTN) in the growth plate of mice. Arch. Orthop. Trauma Surg. (2001) 121:414-416.
17. PUFE T, BARTSCHER M, PETERSEN W, TILLMANN B, MENTLEIN R: Pleiotrophin, an embryonic differentiation and growth factor, is expressed in osteoarthritis. Osteoarthritis Cartilage (2003) 11:260-264.
18. MENTLEIN R, PUFE T: New functions of angiogenic peptides in osteoarthritic cartilage. Curr. Rheumatol. Rev. (2005) 1:37-43.
19. PUFET, GROTH G, GOLDRING MB, TILLMANN B, MENTLEIN R: Effects of pleiotrophin, a heparin-binding growth factor, on human primary and immortalized chondrocytes. Osteoarthritis Cartilage (2006) 15:155-162.
20. CORBLEY MJ: Transformation by Ras suppresses expression of the neurotrophic growth factor pleiotrophin. J. Biol. Chem. (1997) 272:24696-24702.
21. MENG K, RODRIGUEZ-PEÑA A, DIMITROV T et al.: Pleiotrophin signals increased tyrosine phosphorylation of ß-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase ß/ζ. Proc. Natl. Acad. Sci. USA (2000) 97:2603-2608.
22. STOICA GE, KUO A, AIGNER A et al.: Identification of ALK (anaplastic lymphoma kinase) as a receptor for the growth factor pleiotrophin. J. Biol. Chem. (2001) 276:16772-16779.
23. POWERS C, AIGNERA, STOICA GE, MCDONNELL K, WELLSTEIN A: Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J. Biol. Chem. (2002) 277:14153-14158.
24. MOOG-LUTZ C, DEGOUTIN J, GOUZI JY et al.: Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J. Biol. Chem. (2005) 280:26039-26048.
25. ULBRICHT U, ECKERICH C, FILLBRANDT R, WESTPHAL M, LAMSZUS K: RNA interference targeting protein tyrosine phosphatase zeta/receptor-type protein tyrosine phosphatase beta suppresses glioblastoma growth in vitro and in vivo. J. Neurochem. (2006) 98:1497-1506.
26. PEREZ-PINERA P, ALCANTARA S, DIMITROV T, VEGA JA, DEUEL TF: Pleiotrophin disrupts calcium-dependent homophilic cell-cell adhesion and initiates an epithelial-mesenchymal transition. Proc. Natl. Acad. Sci. USA (2006) 103:17795-17800.
27. SOUTTAU B, AHMAND S, RIEGEL AT, WELLSTEIN A: Signal transduction pathways involved in the mitogenic activity of pleiotrophin. J. Biol. Chem. (1997) 272:19588-19593.
28. BLOCH B, NORMAND E, KOVESDI I, BOHLEN P: Expression of the HBNF (heparin-binding neurite-promoting factor) gene in the brain of fetal, neonatal and adult rat: an in situ hybridization study. Brain Res. Dev. Brain Res. (1992) 70:267-278.
29. TONG Y, MENTLEIN R, BUHL R, HUGO H-H, MEHDORN HM, HELD-FEINDT J: Overexpression of midkine contributes to anti-apoptotic effects in human meningiomas. J. Neurochem. (2007) 100:1097-1107.
30. MENTLEIN R, HELD-FEINDT J: Pleiotrophin, an angiogenic and mitogenic growth factor, is expressed in human gliomas. J. Neurochem. (2002) 83:747-753.
31. ZHANG N, ZHONG R, WANG ZY, DEUEL TF: Human breast cancer growth inhibited in vivo by a dominant negative pleiotrophin mutant. J. Biol. Chem. (1997) 272:16733-16736.
32. WEBER D, KLOMP H-J, CZUBAYKO F, WELLSTEIN A, JUHL A: Pleiotrophin can be rate-limiting for pancreatic cancer cell growth. Cancer Res. (2000) 60:5284-5286.
33. MENTLEIN R, HELD-FEINDT J: Angiogenesis factors in gliomas - a new key to tumour therapy? Naturwissenschaften (2003) 90:385-394.
34. PAPADIMITRIOU E, POLYKRATIS A, HATZIAPOSTOLOU M, PARTHYMOU A, POLYTARCHOU C, MIKELIS C: Heparin affin regulatory peptide: a new target for tumour therapy? Curr. Cancer Drug Targets (2004) 4:471-482.
35. IMAI S, KAKSONEN M, RAULO E et al.: Osteoblast recruitment and bone formation enhanced by cell matrix-associated heparin-binding growth-associated molecule (HB-GAM). J. Cell Biol. (1998) 143:1113-1128.
36. TARE RS, OREFFO RO, CLARKE NM, ROACH HI: Pleiotrophin/ osteoblast-stimulating factor 1: dissecting its diverse functions in bone formation. J. Bone Miner. Res. (2002) 17:2009-2020.
37. PETERSEN W, WILDEMANN B, PUFE T, RASCHKE M, SCHMIDMAIER G: The angiogenic peptide pleiotrophin (PTN/HB-GAM) is expressed in fracture healing: an immunohistochemical study in rats. Arch. Orthop. Trauma Surg. (2003) 124:603-607.
38. LI G, CUI Y, MCILMURRAY L, ALLEN WE, WANG H: rhBMP-2, rhVEGF(165), rhPTN and thrombin-related peptide, TP508 induce chemotaxis of human osteoblasts and microvascular endothelial cells. J. Orthop. Res. (2005) 23:680-685.
39. TARE RS, OREFFO RO, SATO K, RAUVALA H, CLARKE NM, ROACH HI: Effects of targeted overexpression of pleiotrophin on postnatal bone development. Biochem. Biophys. Res. Commun. (2002) 298:324-332.
40. YANG X, TARE RS, PARTRIDGE KA et al.: Induction of human osteoprogenitor chemotaxis, proliferation, differentiation, and bone formation by osteoblast stimulating factor-1/pleiotrophin: osteoconductive biomimetic scaffolds for tissue engineering. J. Bone Miner. Res. (2003) 18:47-57.
41. LI G, BUNN JR, MUSHIPE MT, HE Q, CHEN X: Effects of pleiotrophin (PTN) over-expression on mouse long bone development, fracture healing and bone repair. Calcif. Tissue Int. (2005) 76:299-306.
42. OREFFO RO: Growth factors for skeletal reconstruction and fracture repair. Curr. Opin. Investig. Drugs (2004) 5:419-423.
43. MASUDA H, TSUJIMURA A, YOSHIOKA M et al.: Bone mass loss due to estrogen deficiency is compensated in transgenic mice overexpressing human osteoblast stimulating factor-1. Biochem. Biophys. Res. Commun. (1997) 238:528-533.
44. HASHIMOTO-GOTOH T, OHNISHI H, TSUJIMURA A et al.: Bone mass increase specific to the female in a line of transgenic mice overexpressing human osteoblast stimulating factor-1. J. Bone Miner. Metab. (2004) 22:278-282.
45. PUFE T, BARTSCHER M, PETERSEN W, TILLMANN B, MENTLEIN R: Pleiotrophin, an embryonic growth and differentiation factor, is expressed in rheumatoid arthritis. Arthritis Rheum. (2003) 48:660-667.
46. TAKADA T, TORIYAMA K, MURAMATSU H, SONG XJ, TORII S, MURAMATSU T: Midkine, a retinoic acid-inducible heparin-binding cytokine in inflammatory responses: chemotactic activity to neutrophils and association with inflammatory synovitis. J. Biochem. (Tokyo) (1997) 122:453-458.
47. MARUYAMA K, MURAMATSU H, ISHIGURO N, MURAMATSU T: Midkine, a heparin-binding growth factor, is fundamentally involved in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. (2004) 50:1420-1429.
48. BEAU I, COCKSHUTT AM, REGNIER F, CHANY-FOURNIER F, RAULAIS D: Retinoic acid-induced heparin binding protein (RIHB) binds to embryonal chondrocytes and cartilage primarily via proteoglycans. Exp. Cell Res. (1995) 218:531-539.
49. DREYFUS J, BRUNET-DE CARVALHO N, DUPREZ D, RAULAIS D, VIGNY M: HB-GAM/ pleiotrophin but not RIHB/midkine enhances chondrogenesis in micromass culture. Exp. Cell Res. (1998) 241:171-180.
50. TAPP H, HERNANDEZ DJ, NEAME PJ, KOOB TJ: Pleiotrophin inhibits chondrocyte proliferation and stimulates proteoglycan synthesis in mature bovine cartilage. Matrix Biol. (1999) 18:543-556.
51. KUBO M, TAKASE T, MATSUSUE Y, RAUVALA H, IMAI S: Articular cartilage degradation and de-differentiation of chondrocytes by the systemic administration of retinyl acetate-ectopic production of osteoblast stimulating factor-1 by chondrocytes in mice. Osteoarthritis Cartilage (2002) 10:968-976.
52. SANCHEZ C, DEBERG MA, PICCARDI N, MSIKA P, REGINSTER JY, HENROTIN YE: Osteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes. This effect is mimicked by interleukin-6,-1 beta and oncostatin M pre-treated non-sclerotic osteoblasts. Osteoarthritis Cartilage (2005) 13:979-987.
53. STITIK TP, ALTSCHULER E, FOYE PM: Pharmacotherapy of osteoarthritis. Am. J. Phys. Med. Rehabil. (2006) 85(Suppl. 11):S15-S28.
54. AIGNER T, SACHSE A, GEBHARD PM, ROACH HI: Osteoarthritis: pathobiology-targets and ways for therapeutic intervention. Adv. Drug Deliv. Rev. (2006) 58:128-149.
55. ROACH HI, AIGNERT, SODER S, HAAG J, WELKERLING H: Pathobiology of osteoarthritis: pathomechanisms and potential therapeutic targets. Curr. Drug Targets (2007) 8:271-282.
56. HENROTIN Y, KURZ B: Antioxidant to treat osteoarthritis: dream or reality? Curr. Drug Targets (2007) 8:347-357.
57. GELSE K, JIANG QJ, AIGNER T et al.: Fibroblast-mediated delivery of growth factor complementary DNA into mouse joints induces chondrogenesis but avoids the disadvantages of direct viral gene transfer. Arthritis Rheum. (2001) 44:1943-1953.
58. VAN BEUNINGEN HM, GLANSBEEK HL, VAN DER KRAAN PM, VAN DEN BERG WB: Differential effects of local application of BMP-2 or TGF-beta 1 on both articular cartilage composition and osteophyte formation. Osteoarthritis Cartilage (1998) 6:306-317.
59. VAN DEN BERG WB, VAN DER KRAAN PM, SCHARSTUHL A, VAN BEUNINGEN HM: Growth factors and cartilage repair. Clin. Orthop. Relat. Res. (2001) 391(Suppl.):S244-S250.